Literature DB >> 10768948

Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A.

J A Chaddock1, J R Purkiss, L M Friis, J D Broadbridge, M J Duggan, S J Fooks, C C Shone, C P Quinn, K A Foster.   

Abstract

Clostridial neurotoxins potently and specifically inhibit neurotransmitter release in defined cell types by a mechanism that involves cleavage of specific components of the vesicle docking/fusion complex, the SNARE complex. A derivative of the type A neurotoxin from Clostridium botulinum (termed LH(N)/A) that retains catalytic activity can be prepared by proteolysis. The LH(N)/A, however, lacks the putative native binding domain (H(C)) of the neurotoxin and is thus unable to bind to neurons and effect inhibition of neurotransmitter release. Here we report the chemical conjugation of LH(N)/A to an alternative cell-binding ligand, wheat germ agglutinin (WGA). When applied to a variety of cell lines, including those that are ordinarily resistant to the effects of neurotoxin, WGA-LH(N)/A conjugate potently inhibits secretory responses in those cells. Inhibition of release is demonstrated to be ligand mediated and dose dependent and to occur via a mechanism involving endopeptidase-dependent cleavage of the natural botulinum neurotoxin type A substrate. These data confirm that the function of the H(C) domain of C. botulinum neurotoxin type A is limited to binding to cell surface moieties. The data also demonstrate that the endopeptidase and translocation functions of the neurotoxin are effective in a range of cell types, including those of nonneuronal origin. These observations lead to the conclusion that a clostridial endopeptidase conjugate that can be used to investigate SNARE-mediated processes in a variety of cells has been successfully generated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768948      PMCID: PMC97463          DOI: 10.1128/IAI.68.5.2587-2593.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities.

Authors:  B Hallis; B A James; C C Shone
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

2.  Channels formed by botulinum, tetanus, and diphtheria toxins in planar lipid bilayers: relevance to translocation of proteins across membranes.

Authors:  D H Hoch; M Romero-Mira; B E Ehrlich; A Finkelstein; B R DasGupta; L L Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

3.  Wheat germ agglutinin. Molecular characteristics and specificity for sugar binding.

Authors:  Y Nagata; M M Burger
Journal:  J Biol Chem       Date:  1974-05-25       Impact factor: 5.157

4.  The origin, structure, and pharmacological activity of botulinum toxin.

Authors:  L L Simpson
Journal:  Pharmacol Rev       Date:  1981-09       Impact factor: 25.468

Review 5.  Neurospecific binding, internalization, and retrograde axonal transport.

Authors:  J L Halpern; E A Neale
Journal:  Curr Top Microbiol Immunol       Date:  1995       Impact factor: 4.291

6.  Lectin-mediated bioadhesion: binding characteristics of plant lectins on the enterocyte-like cell lines Caco-2, HT-29 and HCT-8.

Authors:  F Gabor; M Stangl; M Wirth
Journal:  J Control Release       Date:  1998-11-13       Impact factor: 9.776

7.  Mouse spinal cord in cell culture. I. Morphology and intrinsic neuronal electrophysiologic properties.

Authors:  B R Ransom; E Neale; M Henkart; P N Bullock; P G Nelson
Journal:  J Neurophysiol       Date:  1977-09       Impact factor: 2.714

8.  The effect of botulinum neurotoxins on the release of insulin from the insulinoma cell lines HIT-15 and RINm5F.

Authors:  R S Boyd; M J Duggan; C C Shone; K A Foster
Journal:  J Biol Chem       Date:  1995-08-04       Impact factor: 5.157

9.  Diphtheria toxin entry into cells is facilitated by low pH.

Authors:  K Sandvig; S Olsnes
Journal:  J Cell Biol       Date:  1980-12       Impact factor: 10.539

10.  Clostridial neurotoxins and substrate proteolysis in intact neurons: botulinum neurotoxin C acts on synaptosomal-associated protein of 25 kDa.

Authors:  L C Williamson; J L Halpern; C Montecucco; J E Brown; E A Neale
Journal:  J Biol Chem       Date:  1996-03-29       Impact factor: 5.157

View more
  18 in total

1.  Re-engineering the target specificity of Clostridial neurotoxins - a route to novel therapeutics.

Authors:  K A Foster; E J Adams; L Durose; C J Cruttwell; E Marks; C C Shone; J A Chaddock; C L Cox; C Heaton; J M Sutton; J Wayne; F C G Alexander; D F Rogers
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 2.  Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting.

Authors:  B R Singh
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 3.  Botulinum toxin for pain.

Authors:  Roberto Casale; Valeria Tugnoli
Journal:  Drugs R D       Date:  2008

Review 4.  Selective Manipulation of Neural Circuits.

Authors:  Hong Geun Park; Jason B Carmel
Journal:  Neurotherapeutics       Date:  2016-04       Impact factor: 7.620

5.  The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions.

Authors:  B Vijayalakshmi Ayyar; K Roger Aoki; M Zouhair Atassi
Journal:  Infect Immun       Date:  2015-01-26       Impact factor: 3.441

Review 6.  Botulinum toxins--cause of botulism and systemic diseases?

Authors:  H Böhnel; F Gessler
Journal:  Vet Res Commun       Date:  2005-05       Impact factor: 2.459

7.  Efficacy and safety of serial injections of botulinum toxin A in children with spastic cerebral palsy.

Authors:  Ya-Jie Wang; Bao-Qin Gao
Journal:  World J Pediatr       Date:  2013-11-14       Impact factor: 2.764

8.  A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis.

Authors:  Emmanuel Somm; Nicolas Bonnet; Alberto Martinez; Philip M H Marks; Verity A Cadd; Mark Elliott; Audrey Toulotte; Serge L Ferrari; René Rizzoli; Petra S Hüppi; Elaine Harper; Shlomo Melmed; Richard Jones; Michel L Aubert
Journal:  J Clin Invest       Date:  2012-08-01       Impact factor: 14.808

Review 9.  Clinical uses of botulinum neurotoxins: current indications, limitations and future developments.

Authors:  Sheng Chen
Journal:  Toxins (Basel)       Date:  2012-10-19       Impact factor: 4.546

Review 10.  Botulinum neurotoxin for pain management: insights from animal models.

Authors:  Flaminia Pavone; Siro Luvisetto
Journal:  Toxins (Basel)       Date:  2010-12-21       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.